We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Integrated Research is a software-application business based in Australia. Integrated Research shares (IRI) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Integrated Research has a trailing 12-month revenue of around $78.5 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Long-term investing
| 52-week range | $1.11 - $2.78 |
|---|---|
| 50-day moving average | $1.2699 |
| 200-day moving average | $1.8149 |
| Target price | $1.5 |
| PE ratio | 24.1304 |
| Dividend yield | $0.037 (3.3%) |
| Earnings per share (TTM) | $0.046 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$1.11
| 1 week (2022-01-10) | -3.90% |
|---|---|
| 1 month (2021-12-17) | -5.93% |
| 3 months (2021-10-15) | -31.69% |
| 6 months (2021-07-17) | -37.64% |
| 1 year (2021-01-15) | -55.60% |
|---|---|
| 2 years (2020-01-17) | -62.12% |
| 3 years (2019-01-17) | -51.74% |
| 5 years (2017-01-17) | -59.04% |
Valuing Integrated Research stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Integrated Research 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Integrated Research 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Integrated Research shares trade at around 24x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Integrated Research 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.5 million (£0.0 million).
The EBITDA is a measure of a Integrated Research 's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $78.5 million |
|---|---|
| Operating margin TTM | 12.46% |
| Gross profit TTM | $78.5 million |
| Return on assets TTM | 4.45% |
| Return on equity TTM | 9.57% |
| Profit margin | 10.11% |
| Book value | 0.484 |
| Market capitalisation | $191.4 million |
TTM: trailing 12 months
Dividend payout ratio: 81.52% of net profits
Recently Integrated Research has paid out, on average, around 81.52% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.83% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Integrated Research shareholders could enjoy a 3.83% return on their shares, in the form of dividend payments. In Integrated Research 's case, that would currently equate to about A$0.037 per share.
Integrated Research 's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 1 September 2020 (the "ex-dividend date").
Over the last 12 months, Integrated Research 's shares have ranged in value from as little as $1.11 up to $2.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Integrated Research 's is 0.761. This would suggest that Integrated Research 's shares are less volatile than average (for this exchange).
Integrated Research Limited designs, develops, implements, and sells systems and applications management computer software for business-critical computing, and unified communication and payment networks. The company offers Prognosis, an integrated suite of monitoring and management software designed to give an organization's management and technical personnel operational insight into the HP NonStop platform, distributed system servers, unified communications, payment environments, and the business applications. It also provides testing, maintenance, and professional services, as well as software as a service solution. The company offers its products in approximately 60 countries through direct sales offices in the United States, the United Kingdom, Germany, Singapore, and Australia, as well as through channel-driven distribution networks internationally. It serves stock exchanges, banks, credit card companies, telecommunications carriers, service providers, and manufacturers. The company was incorporated in 1988 and is based in North Sydney, Australia.
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
Some states are delaying the school year while others discuss using rapid antigen tests in classrooms.
You'll fall for these Autumn flight deals on dozens of domestic and international routes.
Despite recent gains, shares in BNPL leader Afterpay are down 20% over the past month.
The 10 biggest movers on the ASX for Friday 14 January 2022.
Australia and England meet for an historic Ashes Test in Hobart.
The Korean-designed KF94 mask may offer greater protection than a cloth mask.
Spoiler alert: The shag cut is still in.
RAQ Apparel founder Sophia Argyropoulos chats the inspo for Abbie Chatfield swimwear collab and the secret to finding the perfect bikini.
